The DYNAMO-GB project, led by the RADOPT team under Pr Elizabeth Cohen-Jonathan Moyal, has received €339,984 in funding from the INSERM's MCMP call for projects. The goal is to better understand the resistance mechanisms of glioblastoma to Tumor Treating Fields (TTFields) to develop more personalized treatments.
Glioblastoma, the most common and aggressive primary brain tumor, has a poor prognosis despite therapeutic advances. TTFields, a therapy using alternating electric fields, have improved survival but show heterogeneous efficacy and frequent resistance.
The DYNAMO-GB project focuses on the tumor microenvironment, a complex ecosystem influencing disease progression and treatment response. The hypothesis is that TTFields induce adaptations in this microenvironment that promote resistance mechanisms.
To decipher these mechanisms, DYNAMO-GB will track the evolution of the tumor microenvironment throughout TTFields treatment. A multidisciplinary approach will integrate spatial analyses of tumor tissue (transcriptomics, proteomics), study of circulating biomarkers, multiparametric MRI imaging, bioinformatics, and artificial intelligence (AI), along with functional validation on patient-derived organoids. The aim is to identify biological and imaging signatures predicting treatment response and revealing new therapeutic targets.
Led and coordinated by the RADOPT team (Dr Valérie Gouazé-Andersson, Dr Pauline Deshors, Pr Elizabeth Cohen-Jonathan Moyal, IUCT-Oncopole), the project combines expertise in biology, imaging, bioinformatics, and AI. AI approaches will be conducted with Ahmad Berjaoui, an AI expert from IRT Saint Exupéry. The international consortium also includes the TONIC team at CHU de Toulouse-Purpan (Dr Margaux Roques) and the CNRS team (Pr Tathiane Malta, Brazil).
This funding also strengthens the RADOPT team's position in developing integrated approaches at the interface of biology, imaging, and artificial intelligence to address the challenges of precision medicine in neuro-oncology.
